TABLE 2B.
10‐year CI of an SMN and competing events and event‐free survival according to early response and final risk group
| Secondary malignancies | Competing events | Event‐free survival | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameters | Pts. | Events | 10‐year CI | p‐Value | Events | 10‐year CI | p‐Value | 10‐year EFS | p‐value |
| Prednisone response | |||||||||
| Good | 1090 | 11 | 1.2% ± 0.4% | 0.456 | 183 | 18.9% ± 1.3% | <0.001 | 79.0 ± 1.3% | <0.001 |
| Poor | 117 | 2 | 1.9% ± 1.9% | 37 | 33.8% ± 4.6% | 64.3 ± 4.8% | |||
| BM response on day 15 | |||||||||
| M1 | 607 | 5 | 1.2% ± 0.6% | 0.973 | 73 | 13.9% ± 1.6% | <0.001 | 84.90 ± 1.6% | <0.001 |
| M2 | 316 | 3 | 1.5% ± 0.9% | 72 | 26.2% ± 2.7% | 72.4 ± 2.8% | |||
| M3 | 118 | 1 | 1.1% ± 1.1% | 40 | 39.3% ± 5.0% | 59.6 ± 5.1% | |||
| Remission status on day 33 | |||||||||
| CR | 1176 | 13 | 1.3% ± 0.4% | 0.585 | 199 | 19.9% ± 1.2% | <0.001 | 79.7 ± 1.3% | <0.001 |
| No CR | 30 | 0 | 0.0% ± 0.0% | 15 | 51.5% ± 9.4% | 48.5 ± 9.4% | |||
| MRD group | |||||||||
| Low‐risk | 156 | 2 | 4.3% ± 3.5% | 0.732 | 9 | 7.8% ± 2.5% | <0.001 | 87.8 ± 4.3% | <0.001 |
| Intermediate‐risk | 362 | 4 | 1.2% ± 0.7% | 43 | 17.6% ± 3.0% | 81.2 ± 3.0% | |||
| High‐risk | 32 | 0 | 0.0% ± 0.0% | 9 | 31.5% ± 8.9% | 68.5 ± 8.9% | |||
| Final risk group | |||||||||
| Standard‐risk | 514 | 5 | 0.4% ± 0.3% | 0.265 | 102 | 20.8% ± 1.9% | <0.001 | 78.8 ± 1.9% | <0.001 |
| Intermediate‐risk | 756 | 11 | 1.5% ± 0.5% | 127 | 19.2% ± 1.6% | 79.4 ± 1.6% | |||
| High‐risk | 187 | 3 | 1.8% ± 1.3% | 72 | 41.0% ± 3.8% | 56.9 ± 3.9% | |||
Note: Analyses were only performed for those parameters with available results.
Abbreviations: BM, bone marrow; CI, cumulative incidence; CR, complete remission; EFS, event‐free survival; MRD, minimal residual disease; Pts, patients; SMN, secondary malignant neoplasm.